Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
167.3 USD | -0.30% | +1.60% | +7.95% |
Apr. 25 | Cigna to offer Humira rivals with $0 copay at specialty pharmacy | RE |
Apr. 25 | AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint | MT |
Financials (USD)
Sales 2024 * | 54.57B | Sales 2025 * | 57.78B | Capitalization | 297B |
---|---|---|---|---|---|
Net income 2024 * | 9.08B | Net income 2025 * | 11.09B | EV / Sales 2024 * | 6.43 x |
Net Debt 2024 * | 53.67B | Net Debt 2025 * | 45.01B | EV / Sales 2025 * | 5.92 x |
P/E ratio 2024 * |
30.3
x | P/E ratio 2025 * |
24.9
x | Employees | 50,000 |
Yield 2024 * |
3.73% | Yield 2025 * |
3.88% | Free-Float | 96.75% |
Latest transcript on AbbVie Inc.
1 day | -0.30% | ||
1 week | +1.60% | ||
Current month | -8.13% | ||
1 month | -6.30% | ||
3 months | +1.31% | ||
6 months | +15.17% | ||
Current year | +7.95% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Gonzalez
CEO | Chief Executive Officer | 70 | 12-12-31 |
Scott Reents
DFI | Director of Finance/CFO | 57 | 12-12-31 |
Robert Michael
PSD | President | 53 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Roxanne Austin
BRD | Director/Board Member | 63 | 12-12-31 |
Edward Rapp
BRD | Director/Board Member | 66 | 12-12-31 |
Director/Board Member | 70 | 12-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
7.12% | 6 M€ | 0.00% | - | |
6.85% | 18 M€ | +3.04% | - | |
6.26% | 13 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 167.3 | -0.30% | 5,502,318 |
24-04-24 | 167.8 | -1.03% | 4,074,765 |
24-04-23 | 169.5 | +0.98% | 4,084,105 |
24-04-22 | 167.9 | +0.89% | 5,580,685 |
24-04-19 | 166.4 | +1.06% | 5,532,492 |
Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.95% | 297B | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+13.45% | 219B | |
+6.04% | 199B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B | |
+2.07% | 117B |
- Stock Market
- Equities
- ABBV Stock